FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3105209713> ?p ?o ?g. }

• W3105209713 endingPage "e034010" @default.
• W3105209713 startingPage "e034010" @default.
• W3105209713 abstract "Objectives Use of immune checkpoint inhibitors as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the efficacy of IO alone with that of IC as first-line treatment for advanced NSCLC. Design Systematic review. Data sources PubMed, the Cochrane Library and Embase for related studies on NSCLC; ClinicalTrials.gov, American Society of Clinical Oncology Meeting Library and World Conference on Lung Cancer for relevant conference abstracts (to July 2019). Eligibility criteria Articles meeting the following criteria were selected: (1) randomised controlled trials on NSCLC treatment, (2) all individuals in the studies had not received treatment previously and (3) research on IO monotherapy using programmed death-1/programmed death ligand-1 (PD-L1) inhibitors or IC. Data extraction and synthesis After reading the original literature, two reviewers independently extracted the relevant information. The primary outcomes were progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs). Results Overall, 10 randomised controlled clinical trials (n=5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumour PD-L1 expression was at least 50% (HR: 1.81, 95% CI: 1.18 to 2.78) and yielded a better OS and PFS when tumour PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However, the incidence of irAEs was higher for IO than for IC. Conclusions The findings of the indirect comparison indicate that IC as first-line treatment for advanced NSCLC is significantly more effective than IO in patients with PD-L1 expression in at least 50% of tumour cells. Trial registration number CRD 42018116589." @default.
• W3105209713 created "2020-11-23" @default.
• W3105209713 creator A5008283041 @default.
• W3105209713 creator A5018073672 @default.
• W3105209713 creator A5037506720 @default.
• W3105209713 creator A5055751859 @default.
• W3105209713 creator A5077920175 @default.
• W3105209713 creator A5083373236 @default.
• W3105209713 creator A5091081725 @default.
• W3105209713 date "2020-11-01" @default.
• W3105209713 modified "2023-10-03" @default.
• W3105209713 title "Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review" @default.
• W3105209713 cites W1617971067 @default.
• W3105209713 cites W1955438485 @default.
• W3105209713 cites W1964435302 @default.
• W3105209713 cites W2005947177 @default.
• W3105209713 cites W2032095501 @default.
• W3105209713 cites W2037139573 @default.
• W3105209713 cites W2065972613 @default.
• W3105209713 cites W2099326967 @default.
• W3105209713 cites W2110305039 @default.
• W3105209713 cites W2116607009 @default.
• W3105209713 cites W2140699272 @default.
• W3105209713 cites W2157823046 @default.
• W3105209713 cites W2210453860 @default.
• W3105209713 cites W2289841322 @default.
• W3105209713 cites W2296139876 @default.
• W3105209713 cites W2527905628 @default.
• W3105209713 cites W2585755651 @default.
• W3105209713 cites W2591772299 @default.
• W3105209713 cites W2619866304 @default.
• W3105209713 cites W2635951006 @default.
• W3105209713 cites W2769123158 @default.
• W3105209713 cites W2781525129 @default.
• W3105209713 cites W2796582438 @default.
• W3105209713 cites W2806145489 @default.
• W3105209713 cites W2808572932 @default.
• W3105209713 cites W2883427337 @default.
• W3105209713 cites W2888059202 @default.
• W3105209713 cites W2892009523 @default.
• W3105209713 cites W2892640821 @default.
• W3105209713 cites W2898187558 @default.
• W3105209713 cites W2900174742 @default.
• W3105209713 cites W2925446385 @default.
• W3105209713 cites W2944229311 @default.
• W3105209713 cites W2946386783 @default.
• W3105209713 cites W2946950110 @default.
• W3105209713 cites W2947247246 @default.
• W3105209713 cites W2958498622 @default.
• W3105209713 cites W4253858363 @default.
• W3105209713 cites W4294215472 @default.
• W3105209713 doi "https://doi.org/10.1136/bmjopen-2019-034010" @default.
• W3105209713 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7682470" @default.
• W3105209713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33444168" @default.
• W3105209713 hasPublicationYear "2020" @default.
• W3105209713 type Work @default.
• W3105209713 sameAs 3105209713 @default.
• W3105209713 citedByCount "6" @default.
• W3105209713 countsByYear W31052097132022 @default.
• W3105209713 countsByYear W31052097132023 @default.
• W3105209713 crossrefType "journal-article" @default.
• W3105209713 hasAuthorship W3105209713A5008283041 @default.
• W3105209713 hasAuthorship W3105209713A5018073672 @default.
• W3105209713 hasAuthorship W3105209713A5037506720 @default.
• W3105209713 hasAuthorship W3105209713A5055751859 @default.
• W3105209713 hasAuthorship W3105209713A5077920175 @default.
• W3105209713 hasAuthorship W3105209713A5083373236 @default.
• W3105209713 hasAuthorship W3105209713A5091081725 @default.
• W3105209713 hasBestOaLocation W31052097131 @default.
• W3105209713 hasConcept C121608353 @default.
• W3105209713 hasConcept C126322002 @default.
• W3105209713 hasConcept C143998085 @default.
• W3105209713 hasConcept C197934379 @default.
• W3105209713 hasConcept C2776256026 @default.
• W3105209713 hasConcept C2776478404 @default.
• W3105209713 hasConcept C2776694085 @default.
• W3105209713 hasConcept C2777701055 @default.
• W3105209713 hasConcept C535046627 @default.
• W3105209713 hasConcept C71924100 @default.
• W3105209713 hasConcept C95190672 @default.
• W3105209713 hasConceptScore W3105209713C121608353 @default.
• W3105209713 hasConceptScore W3105209713C126322002 @default.
• W3105209713 hasConceptScore W3105209713C143998085 @default.
• W3105209713 hasConceptScore W3105209713C197934379 @default.
• W3105209713 hasConceptScore W3105209713C2776256026 @default.
• W3105209713 hasConceptScore W3105209713C2776478404 @default.
• W3105209713 hasConceptScore W3105209713C2776694085 @default.
• W3105209713 hasConceptScore W3105209713C2777701055 @default.
• W3105209713 hasConceptScore W3105209713C535046627 @default.
• W3105209713 hasConceptScore W3105209713C71924100 @default.
• W3105209713 hasConceptScore W3105209713C95190672 @default.
• W3105209713 hasIssue "11" @default.
• W3105209713 hasLocation W31052097131 @default.
• W3105209713 hasLocation W31052097132 @default.
• W3105209713 hasOpenAccess W3105209713 @default.
• W3105209713 hasPrimaryLocation W31052097131 @default.
• W3105209713 hasRelatedWork W2041803801 @default.
• W3105209713 hasRelatedWork W2055244776 @default.

• next